Filtered By:
Drug: Januvia

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 84 results found since Jan 2013.

Regional, age, and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ConclusionCV risk factors of TECOS participants are reasonably controlled on average, but differences in CV risk management according to region, sex, and history of prior disease exist. This diversity will enhance generalizability of the trial results.
Source: Diabetes, Obesity and Metabolism - January 20, 2015 Category: Endocrinology Authors: M. A. Bethel, J.B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, Tags: ORIGINAL ARTICLE Source Type: research

Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4
Conclusions In obese Type 2 diabetic mice, in the absence of hypoglycaemic effects, inhibition of DPP-4 decreases LV passive stiffness and improves global LV performance. These effects seem at least partially mediated by stimulatory effects on the myocardial cGMP–PKG pathway and, hence, on the phosphorylation status of titin and the hereto coupled cardiomyocyte stiffness modulus.
Source: Cardiovascular Research - November 24, 2014 Category: Cardiology Authors: Hamdani, N., Hervent, A.-S., Vandekerckhove, L., Matheeussen, V., Demolder, M., Baerts, L., De Meester, I., Linke, W. A., Paulus, W. J., De Keulenaer, G. W. Tags: Cardiac biology and remodelling Source Type: research

Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: possible role of epigenetic regulation.
Abstract Metabolic syndrome (MetS) is a complex medical disorder characterized by insulin resistance, hypertension, and high risk of coronary disease and stroke. Microvascular rarefaction and endothelial dysfunction have also been linked with MetS, and recent evidence from clinical studies supports the efficacy of incretin-based antidiabetic therapies for vascular protection in diabetes. Previous studies pointed out the importance of dipeptidyl peptidase-4 (DPP-4) inhibition in endothelial cells due to getting protection against metabolic pathologies. We therefore aimed to investigate the acute effects of a DPP-4 ...
Source: Molecular Biology Reports - May 18, 2014 Category: Molecular Biology Authors: Amber CF, Zeynep TK, Evren O, Yusuf B, Can AK, Belma T Tags: Mol Biol Rep Source Type: research

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic agents. TECOS will evaluate the effects of adding sitagliptin to usual diabetes care on cardiovascular outcomes and clinical safety. TECOS is a pragmatic, academically run, multinational, randomized, double-blind, placebo-controlled, event-driven trial recruiting approximately 14,000 patients in 38 countries who have type 2 diabetes (T2DM), are at least 50 years old, have cardiovascular disease, and have an hemoglobin A1c value between 6.5% and 8.0%. Eligible participan...
Source: American Heart Journal - October 25, 2013 Category: Cardiology Authors: Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, Rury R. Holman Tags: Trial Design Source Type: research

All‐cause mortality and cardiovascular effects associated with the DPP‐IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population
ConclusionIn a retrospective analysis, sitagliptin monotherapy compared with metformin monotherapy was not associated with any statistical significant increased risk of all‐cause mortality or the composite endpoint, but was associated with an increased likelihood of changing glucose‐lowering treatment.
Source: Diabetes, Obesity and Metabolism - September 10, 2013 Category: Endocrinology Authors: N. M. Scheller, U. M. Mogensen, C. Andersson, A. Vaag, C. Torp‐Pedersen Tags: ORIGINAL ARTICLE Source Type: research

All‐cause mortality and cardiovascular effects associated with the DPPIV‐inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population
ConclusionIn a retrospective analysis, sitagliptin monotherapy compared with metformin monotherapy was not associated with any statistical significant increased risk of all‐cause mortality or the composite endpoint, but was associated with an increased likelihood of changing glucose‐lowering treatment.
Source: Diabetes, Obesity and Metabolism - August 21, 2013 Category: Endocrinology Authors: Nikolai Madrid Scheller, Ulrik Madvig Mogensen, Charlotte Andersson, Allan Vaag, Christian Torp‐Pedersen Tags: Original Article Source Type: research

Efficacy of acute high-intensity interval training in lowering glycemia in patients with type 2 diabetes: diabetes em movimento(r) pilot study.
CONCLUSIONS: HIIT appears to be an effective and safe exercise strategy to acutely control blood glucose in patients with type 2 diabetes. TRIAL FUNDING AND REGISTRATION: Diabetes em Movimento® is funded by Portuguese Foundation for Science and Technology with reference SFRH/BD/47733/2008 and is registered in Current Controlled Trials with reference ISRCTN09240628. PMID: 23757644 [PubMed - in process]
Source: British Journal of Sports Medicine - June 14, 2013 Category: Sports Medicine Authors: Mendes R, Sousa N, Garrido N, Rocha P, Themudo Barata José L, Reis Victor M Tags: Br J Sports Med Source Type: research

Diabetes drugs may be linked to pancreatic cancer
Conclusion This article presents important concerns that glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors could potentially increase the risk of inflammation and cancerous changes in the pancreas. The agencies that regulate medicines in Europe and the USA are aware of these issues, and told the BMJ that their analyses show increased reporting of pancreatic cancer among people taking these types of drugs. However, the agencies note that it has not been established whether these drugs directly cause the adverse effects seen in the pancreas. Both agencies are reviewing emerging eviden...
Source: NHS News Feed - June 10, 2013 Category: Consumer Health News Tags: Medication Diabetes QA articles Source Type: news

Efficacy of acute high-intensity interval training in lowering glycemia in patients with type 2 diabetes: diabetes em movimento(r) pilot study
Conclusions HIIT appears to be an effective and safe exercise strategy to acutely control blood glucose in patients with type 2 diabetes. Trial funding and registration Diabetes em Movimento® is funded by Portuguese Foundation for Science and Technology with reference SFRH/BD/47733/2008 and is registered in Current Controlled Trials with reference ISRCTN09240628.
Source: British Journal of Sports Medicine - June 10, 2013 Category: Sports Medicine Authors: Mendes, R., Sousa, N., Garrido, N., Rocha, P., Themudo Barata Jose, L., Reis Victor, M. Tags: ORAL PRESENTATIONS: EXERCISE MEDICINE Source Type: research